Abstract
Transcatheter aortic valves have been implanted in New Zealand since August 2008 for severe, symptomatic aortic stenosis (AS) in patients considered high risk for traditional surgical valve replacement. The self expanding Medtronic CoreValve™ (CV) and balloon expandable Edwards Sapien™ (EV) valve were used. We describe our experience with cost-effective analysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.